The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
Dr. Samy Suissa and Dr. Meg Richards
Advertisement
Articles by Dr. Samy Suissa and Dr. Meg Richards
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Is FDA Streamlining Regulations in the Biosimilar Space?
2
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
3
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
4
When Borders Become Bottlenecks: How Pharma Should Adapt to the New Geopolitical Lens
5
